Comparing the risk of cardiovascular disease between degarelix and gonadotropin-releasing hormone agonists:a systematic review and meta-analysis
Open Access
- 1 October 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1523794
Abstract
Background: Regarding the comparison of cardiovascular disease risk between gonadotropin-releasing hormone (GnRH) antagonists and GnRH agonists, there are discrepancies in results from different studies. Therefore, this meta-analysis was conducted to investigate whether degarelix could reduce cardiovascular disease risk.Methods: We systematically searched the PubMed, Embase, Web of Science, and Cochrane Library databases with a search time limit of up to December 2023 for articles focusing on the use of degarelix, a GnRH antagonist, in prostate cancer, with an emphasis on articles comparing degarelix to GnRH agonists. Study endpoints included major adverse cardiovascular events, stroke, all-cause mortality, myocardial infarction, heart failure, and arrhythmia.Results: A total of 1320 articles were retrieved, of which eight met our inclusion criteria and involved 138–065 patients. The pooled results showed no difference in the risk of major adverse cardiovascular events (hazard ratio [HR]=0.94, 95% confidence interval [CI]: 0.65–1.35; P=0.73), stroke (HR=0.89, 95% CI: 0.62–1.27; P=0.52), myocardial infarction (HR=0.98, 95% CI: 0.70–1.37; P=0.91), all-cause mortality (HR=1.09, 95% CI: 0.73–1.65; P=0.67), and arrhythmia (risk ratio=0.64, 95% CI: 0.15–2.76; P=0.55) between degarelix and GnRH agonists. However, degarelix reduced the risk of heart failure (HR=0.56, 95% CI: 0.36–0.88; P=0.01).Conclusion: Further clarification on the effects of different androgen deprivation therapy modalities on cardiovascular disease is needed from future and larger prospective randomized controlled trials.Keywords
This publication has 41 references indexed in Scilit:
- Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer TreatmentJAMA Network Open, 2021
- Gonadotropin‐releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin‐releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro studyThe Prostate, 2021
- Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databasesInternational Journal of Cancer, 2020
- Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practiceWorld Journal of Urology, 2020
- The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversyCritical Reviews in Oncology/Hematology, 2013
- Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?Diabetes/Metabolism Research and Reviews, 2012
- Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate CancerJAMA, 2011
- Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancerCancer, 2009
- Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen‐deprivation therapyCancer, 2005
- The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged MenJAMA, 2002